Codexis Announces RNA Therapeutics Manufacturing Workshop at TIDES USA
April 19 2023 - 3:05PM
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,
today announced it will host a pre-conference workshop highlighting
the role of an enzymatic approach to support RNA-based therapeutics
manufacturing at the TIDES USA annual meeting being held May 7-10,
2023, in San Diego, CA. The workshop will be held live and
virtually on Sunday, May 7, 2023.
Ribonucleic acid (RNA) as a therapeutic modality has gained
tremendous traction in recent years with the growing number of
messenger RNA (mRNA) vaccines and small interfering RNA (siRNA)
candidates advancing in clinical studies. However, large-scale
production faces complex challenges in nucleic acids quality and
quantity, as well as overall economics. At TIDES USA, Codexis will
showcase how engineered enzymes can overcome these difficulties to
enable scalable and sustainable manufacturing.
Presentation Details
Title: Engineered Enzymes to Overcome
Scalability and Sustainability Challenges of Nucleic Acid
Therapeutics ManufacturingDate: Sunday, May 7,
2023Time: 12:30 pm – 1:30 pm PT
Location: Manchester Grand Hyatt, San Diego,
CA
An archive of the presentation will be available to registered
attendees within the TIDES USA platform. The presentation will also
be available on Codexis’ website, www.codexis.com.
About Codexis
Codexis is a leading enzyme engineering company leveraging our
proprietary CodeEvolver® technology platform to discover, develop
and enhance novel, high-performance enzymes and other classes of
proteins. Codexis enzymes solve for real-world challenges
associated with small molecule pharmaceuticals manufacturing,
nucleic acid synthesis and genomic sequencing, and – as
biotherapeutic candidates – they have the potential to treat
challenging diseases. Our unique enzymes drive improvements such as
higher yields, reduced energy usage and waste generation, improved
efficiency in manufacturing, greater sensitivity in genomic and
diagnostic applications and potentially more efficacious
therapeutics. For more information, visit www.codexis.com.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Codexis, they
are forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements regarding how engineered enzymes have the potential to
enable scalable and sustainable manufacturing of mRNA vaccines and
siRNA product candidates. You should not place undue reliance on
these forward-looking statements because they involve known and
unknown risks, uncertainties and other factors that are, in some
cases, beyond Codexis’ control and that could materially affect
actual results. Additional information about factors that could
materially affect actual results can be found in Codexis’ Annual
Report on Form 10-K filed with the Securities and Exchange
Commission (“SEC”) on February 27, 2023, including under the
caption “Risk Factors,” and in Codexis’ other periodic reports
filed with the SEC. Codexis expressly disclaims any intent or
obligation to update these forward-looking statements, except as
required by law.
For More Information
Investor ContactCarrie McKim(336) 608-9706ir@codexis.com
Media ContactLauren Musto(781) 572-1147media@codexis.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2023 to Jul 2024